• linkedin
  • Increase Font
  • Sharebar

    Long-term TRT improves urinary, erectile function

    ‘Excellent adherence’ points to high satisfaction with treatment, author says

    Bremerhaven, Germany—Long-term testosterone therapy (TT) in hypogonadal men improves urinary function and erectile function compared with untreated controls, according to registry data from a single practice.  

    Also see: Testosterone solution yields improved sex drive, energy

    Ahmad Haider, MD, PhDDr. HaiderAt the AUA annual meeting in San Diego, Ahmad Haider, MD, PhD, a urologist from Bremerhaven, Germany, presented his experience with TT at his practice.

    Dr. Haider and colleagues examined a registry of 658 symptomatic hypogonadal men (mean age, 61 years). At baseline, men had total testosterone levels ≤348 ng/dL. Of the cohort, 360 received injections of testosterone undecanoate (Aveed), 1,000 mg every 12 weeks, following an initial 6-week interval for up to 10 years. All injections were administered in a single office. Some 296 hypogonadal men who opted against testosterone therapy served as the controls. Both groups were followed for a median of 78 months.

    Total testosterone levels increased quickly to 500 ng/dL in the patients who chose testosterone therapy, and remained there through the end of follow-up. There was no change in total testosterone in the controls.

    Prostate volume increased by a mean of 2 mL—from 29.2 mL to 31.1 mL—in the TT group over the 8 years and was unchanged in the controls. The estimated difference in prostate volume was 2 mL (p<.05) between the TT and control groups at year 8 when adjusted for baseline age, weight, waist circumference, fasting glucose level, blood pressure, and lipid levels.

    As expected, the post-void residual volume as measured by ultrasound increased in the control group, from 48.3 mL at baseline to 64.5 mL at last follow-up. In the group that received testosterone undecanoate, post-void residual declined from a mean of 47.3 mL at baseline to a mean of 13.7 mL at the final follow-up.

    The estimated adjusted difference in post-void residual volume was significant in favor of the TT group starting at year 1 (10 mL difference; p<.0001) and remained significant throughout the follow-up, reaching a difference of 53 mL at year 8 (p<.0001).

    Next: IPSS decrease seen in TT group

    Wayne Kuznar
    Wayne Kuznar is a contributor to Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available